Europe — Post Brexit Effect: Update on the Unified Patent Court and the Future of the Unitary Patent

May 17, 2019 1:00pm

James Hayles
European Patent Attorney
Pfizer (Sandwich, United Kingdom)

Paul Inman
Partner
Gowlings WLG (London, United Kingdom)

Moderator

Honorable Teresa Rea
Partner
Crowell & Moring LLP (Washington, DC) (Former Acting Under Secretary of Commerce for Intellectual Property and Former Acting Director of the United States Patent and Trademark Office)

Equipped with the most up to date knowledge, our esteemed panellist will discuss, examine and clarify ambiguous areas of patenting and related regulatory processes in the post-Brexit era:
  • Determining whether the UK can still participate in the UPC after its exit from EU?
    • How does this affect U.S. pharma companies seeking patent protection in the U.K?
  • Reviewing the patent prosecution process and utilisation of the UPC
  • What are the expected outcomes of Brexit to the UPC
    • How will this impact patent prosecution strategies for U.S. pharmaceutical companies looking to obtain Unitary Patents?
  • How will IP case law develop resulting from Brexit?
  • Understanding how influential English court decisions are on the international stage?
  • Determining best practice litigation strategies at the Unified Patent Court to obtain a Unitary Patent